Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multi-omics profiling of chronic immune-mediated skin diseases: SKINERGY protocol and strategic evaluation.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same author

Ex Vivo Confocal Laser Scanning Microscopy for Real-Time Pattern and Single-Cell Analysis in Inflammatory Skin Diseases.

Experimental dermatology·2025
Same author

Impact of soil moisture content on urban tree evaporative cooling and human thermal comfort.

npj urban sustainability·2025
Same author

Delayed pressure urticaria affects chronic spontaneous urticaria treatment response: CURE insights.

European annals of allergy and clinical immunology·2025
Same author

Omalizumab is effective and safe in chronic inducible urticaria (CIndU): Real-world data from a large multi-national UCARE study.

Allergy·2024
Same author

Editorial Expression of Concern: Cytotoxic drug-induced, p53-mediated upregulation of caspase-8 in tumor cells.

Oncogene·2024

Related Experiment Video

Updated: Jul 9, 2026

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin
08:57

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Published on: March 26, 2015

Relapsing-remitting multiple sclerosis: what is the potential for combination therapy?

M Mäurer1, P Rieckmann

  • 1Clinical Research Unit for Multiple Sclerosis and Neuroimmunology, Department of Neurology, Bayerische Julius-Maximilians Universität, Würzburg, Germany.

Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|November 24, 2007
PubMed
Summary

Combining immunomodulating therapies for multiple sclerosis (MS) shows promise for improved safety and efficacy. Further clinical trials are needed to confirm synergistic benefits in relapsing-remitting MS patients.

More Related Videos

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

Related Experiment Videos

Last Updated: Jul 9, 2026

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin
08:57

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Published on: March 26, 2015

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

Area of Science:

  • Neuroimmunology
  • Clinical Pharmacology
  • Neurology

Background:

  • Multiple sclerosis (MS) is a treatable autoimmune disease.
  • Current immunomodulating therapies offer moderate efficacy and face challenges with treatment failure.
  • The need for more effective MS treatments is critical.

Purpose of the Study:

  • To evaluate the safety and efficacy of combination therapies for relapsing-remitting MS.
  • To explore potential synergistic benefits of combining different immunomodulatory agents.
  • To summarize current drug combination strategies and review initial clinical trials in MS.

Main Methods:

  • Review of current immunomodulatory drug targets in MS, including general immunosuppression and targeted approaches.
  • Analysis of potential additive or complementary mechanisms of action.
  • Overview of initial clinical trials investigating combination therapies in relapsing-remitting MS.

Main Results:

  • Combination therapies are being investigated for safety, reduced adverse effects, and synergistic benefits.
  • Targeted approaches interfere with antigen presentation, immune cell transmigration, myelinotoxic factors, and axonal damage.
  • Initial clinical trials are exploring these combination strategies.

Conclusions:

  • Combining immunomodulatory drugs for MS appears rational and promising.
  • Carefully designed clinical trials in selected patient populations are essential.
  • Demonstrating additive or synergistic effects is key to advancing combination therapy in MS.